Search General Info
Search Education
Search Partnering Companies
![CEO 2023 Logo](/sites/default/files/2022-08/264423_BIO_22_CEO_Logo-V.png)
SFA Therapeutics is a clinical-stage oral small molecule, novel immunomodulatory focused company pursuing chronic inflammatory and autoimmune diseases with significant unmet needs.
SFA is seeking $25m in Series A funding to accelerate Phase 2 development of its lead asset, SFA002.
SFA Therapeutics’ lead asset is SFA-002, a first-in-class immunomodulator agent that inhibits IL-17, IL-23, TNF-alpha, and Interferon-gamma. First-in-human Phase 1a proof of concept psoriasis data with SFA002 (n=6) showed a Psoriasis Area Severity Index (PASI) 80% reduction or greater, in all 6 subjects, including durable responses on challenge and re-challenge.
The company is currently enrolling SFA-002 in an open-label (n=30) phase 1b clinical trial on efficacy and safety, measuring cytokine level biomarker data per trial protocol, with Phase 1b data readout in the first half of 2023. SFA Therapeutics has 9 patents covering our drugs, with coverage to 2041.
SFA is seeking $25m in Series A funding to accelerate Phase 2 development of its lead asset, SFA002.
SFA Therapeutics’ lead asset is SFA-002, a first-in-class immunomodulator agent that inhibits IL-17, IL-23, TNF-alpha, and Interferon-gamma. First-in-human Phase 1a proof of concept psoriasis data with SFA002 (n=6) showed a Psoriasis Area Severity Index (PASI) 80% reduction or greater, in all 6 subjects, including durable responses on challenge and re-challenge.
The company is currently enrolling SFA-002 in an open-label (n=30) phase 1b clinical trial on efficacy and safety, measuring cytokine level biomarker data per trial protocol, with Phase 1b data readout in the first half of 2023. SFA Therapeutics has 9 patents covering our drugs, with coverage to 2041.
![](/sites/default/files/hubb_images/6588/attachments/%2520-%2520f1_SFA_20Therapeutics_2C_20Inc__6d98b11e.jpg)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Dermatology
Lead Product in Development:
SFA-002 for Psoriasis
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
![photo](/sites/default/files/hubb_images/6588/photos/user1.Spector.45da11d9.jpeg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved